|
1
|
Yu Y, Luo R, Lu Z, Wei FW, Badgwell D,
Issa JP, Rosen DG, Liu J and Bast RC Jr: Biochemistry and biology
of ARHI (DIRAS3), an imprinted tumor suppressor gene whose
expression is lost in ovarian and breast cancers. Methods Enzymol.
407:455–468. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y,
Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB and Bast RC Jr:
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in
ovarian and breast carcinomas. Proc Natl Acad Sci USA. 96:214–219.
1999. View Article : Google Scholar
|
|
3
|
Tang HL, Hu YQ, Qin XP, Jazag A, Yang H,
Yang YX, Yang XN, Liu JJ, Chen JM, Guleng B and Ren JL: Aplasia ras
homolog member I is downregulated in gastric cancer and silencing
its expression promotes cell growth in vitro. J Gastroenterol
Hepatol. 27:1395–1404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu X, Liang L, Dong L, Yu Z and Fu X:
Effect of ARHI on lung cancer cell proliferation, apoptosis and
invasion in vitro. Mol Biol Rep. 40:2671–2678. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bao JJ, Le XF, Wang RY, Yuan J, Wang L,
Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y and Bast RC Jr:
Reexpression of the tumor suppressor gene ARHI induces
apoptosis in ovarian and breast cancer cells through a
caspase-independent calpain-dependent pathway. Cancer Res.
62:7264–7272. 2002.PubMed/NCBI
|
|
6
|
Luo RZ, Fang X, Marquez R, Liu SY, Mills
GB, Liao WS, Yu Y and Bast RC: ARHI is a Ras-related small
G-protein with a novel N-terminal extension that inhibits growth of
ovarian and breast cancers. Oncogene. 22:2897–2909. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare
S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS and Bast RC Jr: The
tumor suppressor gene ARHI regulates autophagy and tumor
dormancy in human ovarian cancer cells. J Clin Invest.
118:3917–3929. 2008.PubMed/NCBI
|
|
8
|
Widschwendter M, Siegmund KD, Müller HM,
Fiegl H, Marth C, Müller-Holzner E, Jones PA and Laird PW:
Association of breast cancer DNA methylation profiles with hormone
receptor status and response to tamoxifen. Cancer Res.
64:3807–3813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao
J, Kadota M, Oshimura M, Dent SR, Issa JP and Bast RC Jr:
Epigenetic regulation of ARHI in breast and ovarian cancer
cells. Ann NY Acad Sci. 983:268–277. 2003.PubMed/NCBI
|
|
10
|
Janssen EA, Øvestad IT, Skaland I, Søiland
H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA and Baak JP:
LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast
cancer. Cell Oncol. 31:335–343. 2009.PubMed/NCBI
|
|
11
|
Yang J, Hu A, Wang L, Li B, Chen Y, Zhao
W, Xu W and Li T: NOEY2 mutations in primary breast cancers
and breast hyperplasia. Breast. 18:197–203. 2009. View Article : Google Scholar
|
|
12
|
Yuan J, Luo RZ, Fujii S, Wang L, Hu W,
Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC
Jr and Yu Y: Aberrant methylation and silencing of ARHI, an
imprinted tumor suppressor gene in which the function is lost in
breast cancers. Cancer Res. 63:4174–4180. 2003.PubMed/NCBI
|
|
13
|
Feng W, Marquez RT, Lu Z, Liu J, Lu KH,
Issa JP, Fishman DM, Yu Y and Bast RC Jr: Imprinted tumor
suppressor genes ARHI and PEG3 are the most
frequently down-regulated in human ovarian cancers by loss of
heterozygosity and promoter methylation. Cancer. 112:1489–1502.
2008.PubMed/NCBI
|
|
14
|
Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y,
Bast RC and Li J: Imprinted tumor suppressor gene ARHI induces
apoptosis correlated with changes in DNA methylation in pancreatic
cancer cells. Mol Med Rep. 3:581–587. 2010.PubMed/NCBI
|
|
15
|
Feng W, Lu Z, Luo RZ, Zhang X, Seto E,
Liao WS and Yu Y: Multiple histone deacetylases repress tumor
suppressor gene ARHI in breast cancer. Int J Cancer.
120:1664–1668. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan
J, Lu Z, Bast RC Jr, Feng Y and Yu Y: Re-expression of ARHI
(DIRAS3) induces autophagy in breast cancer cells and enhances the
inhibitory effect of paclitaxel. BMC Cancer. 11:222011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen MY, Liao WS, Lu Z, Bornmann WG,
Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA and Bast RC
Jr: Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit
growth of ovarian cancer cell lines and xenografts while inducing
expression of imprinted tumor suppressor genes, apoptosis, G2/M
arrest, and autophagy. Cancer. 117:4424–4438. 2011. View Article : Google Scholar
|
|
18
|
Luo RZ, Peng H, Xu F, Bao J, Pang Y,
Pershad R, Issa JP, Liao WS, Bast RC Jr and Yu Y: Genomic structure
and promoter characterization of an imprinted tumor suppressor gene
ARHI. Biochim Biophys Acta. 1519:216–222. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu YQ, Si LJ, Ye ZS, Lin ZH and Zhou JP:
Inhibitory effect of ARHI on pancreatic cancer cells and NF-κB
activity. Mol Med Rep. 7:1180–1184. 2013.PubMed/NCBI
|
|
20
|
Dalai I, Missiaglia E, Barbi S, Butturini
G, Doglioni C, Falconi M and Scarpa A: Low expression of ARHI is
associated with shorter progression-free survival in pancreatic
endocrine tumors. Neoplasia. 9:181–183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu Z and Bast RC Jr: The tumor suppressor
gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through
multiple mechanisms. Cell Adh Migr. 7:232–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Shi L, Han C, Wang Y, Yang J, Cao C
and Jiao S: Effects of ARHI on cell cycle progression and apoptosis
levels of breast cancer cells. Tumour Biol. 33:1403–1410. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang J, Lin Y, Li L, Qing D, Teng XM,
Zhang YL, Hu X, Hu Y, Yang P and Han ZG: ARHI, as a novel
suppressor of cell growth and downregulated in human hepatocellular
carcinoma, could contribute to hepatocarcinogenesis. Mol Carcinog.
48:130–140. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fujii S, Luo RZ, Yuan J, Kadota M,
Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC Jr and Yu Y:
Reactivation of the silenced and imprinted alleles of ARHI is
associated with increased histone H3 acetylation and decreased
histone H3 lysine 9 methylation. Hum Mol Genet. 12:1791–1800. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Cui G, Sun L, Wang SJ, Li YL, Meng
YG, Guan Z, Fan WS, Li LA, Yang YZ, You YQ, Fu XY, Yan ZF and Huang
K: STAT3 acetylation-induced promoter methylation is associated
with downregulation of the ARHI tumor-suppressor gene in ovarian
cancer. Oncol Rep. 30:165–170. 2013.PubMed/NCBI
|
|
26
|
Zhang L, Liu P, Li H and Xue F: Effect of
histone deacetylase inhibitors on cell apoptosis and expression of
the tumor suppressor genes RUNX3 and ARHI in ovarian tumors. Mol
Med Rep. 7:1705–1709. 2013.PubMed/NCBI
|
|
27
|
Singh V, Sharma P and Capalash N: DNA
methyltransferase-1 inhibitors as epigenetic therapy for cancer.
Curr Cancer Drug Targets. 13:379–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang J, Yan H and Zhuang S: Histone
deacetylases as targets for treatment of multiple diseases. Clin
Sci. 124:651–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zafar SF, Nagaraju GP and El-Rayes B:
Developing histone deacetylase inhibitors in the therapeutic
armamentarium of pancreatic adenocarcinoma. Expert Opin Ther
Targets. 16:707–718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng W, Shen L, Wen S, Rosen DG, Jelinek
J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr,
Shen Y, Issa JP and Yu Y: Correlation between CpG methylation
profiles and hormone receptor status in breast cancers. Breast
Cancer Res. 9:R572007. View
Article : Google Scholar : PubMed/NCBI
|
